Contrast-enhanced Ultrasound Versus CT Scan for Kidney Stone Patient Management (CEUS)
Primary Purpose
Ultrasonography, Nephrolithiasis
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
CEUS
Non-contrast CT scan
Capping trial
Sponsored by
About this trial
This is an interventional diagnostic trial for Ultrasonography focused on measuring Contrast-enhanced ultrasound, Percutaneous nephrolithotomy
Eligibility Criteria
Inclusion Criteria:
- Age of 18 years or older.
- Renal and/or ureteral stone of any size diagnosed either by ultrasound or CT scan and requiring surgical treatment with percutaneous removal (PCNL).
Exclusion Criteria:
- A second stage PCNL is planned or expected after surgery, entailing that postoperative tube management is pre-determined.
- Subjects with serious illness likely to cause death within the next 5 years, so as to exclude significant metabolic derangements that might lead to adverse surgical outcome.
- Subjects with a history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in Lumason
- Pregnancy, which is a contraindication to both CT scan and ultrasound contrast injection.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
CEUS arm
CT scan plus capping trial arm
Arm Description
On postoperative day 1 (unless not clinically indicated), each subject will undergo CEUS with an administration of Lumason via their pre-placed nephrostomy tube.
On postoperative day 1 (unless not clinically indicated), subjects' pre-placed nephrostomy tube will be capped and they will undergo a low dose non-contrast abdominal CT scan.
Outcomes
Primary Outcome Measures
Radiation exposure dose
For radiation exposure dose measurement in this study, the investigators will use dose metrics obtained from the Digital Imaging and Communications within the scanners or Picture Arching and Communication system (PACS).
Secondary Outcome Measures
Rate of adverse clinical events
Defined as postoperative complications and any unplanned surgery related to the patient's kidney stone
Full Information
NCT ID
NCT03058614
First Posted
February 16, 2017
Last Updated
June 1, 2022
Sponsor
University of California, San Francisco
Collaborators
Oregon Health and Science University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1. Study Identification
Unique Protocol Identification Number
NCT03058614
Brief Title
Contrast-enhanced Ultrasound Versus CT Scan for Kidney Stone Patient Management
Acronym
CEUS
Official Title
Contrast-enhanced Ultrasound Versus CT Scan for Kidney Stone Patient
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Withdrawn
Why Stopped
The research team submitted grants over the course of several years to gain funds to support this research but were unsuccessful in securing the funds. The research team will now focus on other funded studies.
Study Start Date
June 30, 2017 (Anticipated)
Primary Completion Date
May 2, 2022 (Actual)
Study Completion Date
May 2, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, San Francisco
Collaborators
Oregon Health and Science University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will be a randomized controlled study comparing the use of two clinical management strategies in nephrostomy tube management following percutaneous nephrolithotomy (PCNL). The first strategy entails using contrast-enhanced ultrasound (CEUS) to evaluate the renal collecting system (1). This is a new imaging approach applying ultrasound machines with special software in combination with intraluminal ultrasound contrast agent (Lumason) injection, which is an FDA-approved ultrasound contrast agent (2). The second strategy is a nephrostomy tube capping trial combined with low dose non-contrast computed tomography (CT) scan, one of the most frequently utilized clinical management strategies currently used in clinical practice (3).
Detailed Description
This is a multi-center, randomized controlled study comparing the use of CEUS to CT scan plus capping trial immediately following PCNL. A total recruitment target of 1,046 subjects is planned and participants will be randomized into one of the two study arms.
Contrast-enhanced ultrasound (CEUS) arm: On postoperative day 1 (unless not clinically indicated), each subject will undergo CEUS with an administration of Lumason via their pre-placed nephrostomy tube.
Non-contrast CT scan plus capping trial arm: On postoperative day 1 (unless not clinically indicated), subjects' pre-placed nephrostomy tube will be capped and they will undergo a low dose non-contrast abdominal CT scan.
Subsequently, nephrostomy tubes will be managed based on the results from these studies by the treating surgeon.
Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study.
The following investigational regimen will be used only in the CEUS arm:
Experimental Investigation: Lumason at a 2 mL single dose, repeatable once at the time of imaging as needed.
Subjects will be exposed to the randomization schema for 1 day during which they will undergo one of the two diagnostic imaging pathways. After that imaging study is complete, clinical care will proceed as per norm. Clinical and imaging data will be prospectively collected from the time of initial presentation until 6 months after surgery. The total duration of the study is expected to be 5 years to reach target accrual. Therefore, the investigators anticipate that the total duration of this study will be 4 years and 6 months for patient recruitment with the final 6 months used for collecting follow up data.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ultrasonography, Nephrolithiasis
Keywords
Contrast-enhanced ultrasound, Percutaneous nephrolithotomy
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized control study
Masking
Care ProviderInvestigator
Masking Description
The surgical team will be blinded to the randomization outcome of the patient until the day after surgery so as to minimize any bias introduced into their preoperative counseling. After that point, treatment teams will no longer be blinded to randomization.
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CEUS arm
Arm Type
Active Comparator
Arm Description
On postoperative day 1 (unless not clinically indicated), each subject will undergo CEUS with an administration of Lumason via their pre-placed nephrostomy tube.
Arm Title
CT scan plus capping trial arm
Arm Type
Active Comparator
Arm Description
On postoperative day 1 (unless not clinically indicated), subjects' pre-placed nephrostomy tube will be capped and they will undergo a low dose non-contrast abdominal CT scan.
Intervention Type
Drug
Intervention Name(s)
CEUS
Other Intervention Name(s)
Contrast-enhanced ultrasound, CEUS nephrostogram
Intervention Description
In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
Intervention Type
Diagnostic Test
Intervention Name(s)
Non-contrast CT scan
Other Intervention Name(s)
NCCT
Intervention Description
The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.
Intervention Type
Diagnostic Test
Intervention Name(s)
Capping trial
Intervention Description
Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
Primary Outcome Measure Information:
Title
Radiation exposure dose
Description
For radiation exposure dose measurement in this study, the investigators will use dose metrics obtained from the Digital Imaging and Communications within the scanners or Picture Arching and Communication system (PACS).
Time Frame
6 months following surgery
Secondary Outcome Measure Information:
Title
Rate of adverse clinical events
Description
Defined as postoperative complications and any unplanned surgery related to the patient's kidney stone
Time Frame
6 months following surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age of 18 years or older.
Renal and/or ureteral stone of any size diagnosed either by ultrasound or CT scan and requiring surgical treatment with percutaneous removal (PCNL).
Exclusion Criteria:
A second stage PCNL is planned or expected after surgery, entailing that postoperative tube management is pre-determined.
Subjects with serious illness likely to cause death within the next 5 years, so as to exclude significant metabolic derangements that might lead to adverse surgical outcome.
Subjects with a history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in Lumason
Pregnancy, which is a contraindication to both CT scan and ultrasound contrast injection.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Chi, MD
Organizational Affiliation
UCSF Department of Urology
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
28234551
Citation
Chi T, Usawachintachit M, Mongan J, Kohi MP, Taylor A, Jha P, Chang HC, Stoller M, Goldstein R, Weinstein S. Feasibility of Antegrade Contrast-enhanced US Nephrostograms to Evaluate Ureteral Patency. Radiology. 2017 Apr;283(1):273-279. doi: 10.1148/radiol.2016160959. Epub 2016 Oct 19.
Results Reference
background
Citation
Lumason: Prescribing Information [Internet]. [cited 2017 Jan 21]. Available from: http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information
Results Reference
background
PubMed Identifier
23590513
Citation
Sountoulides P, Metaxa L, Cindolo L. Is computed tomography mandatory for the detection of residual stone fragments after percutaneous nephrolithotomy? J Endourol. 2013 Nov;27(11):1341-8. doi: 10.1089/end.2012.0253. Epub 2013 Jul 9.
Results Reference
background
Learn more about this trial
Contrast-enhanced Ultrasound Versus CT Scan for Kidney Stone Patient Management
We'll reach out to this number within 24 hrs